FDA grants GSK’s neladalkib accelerated approval for ALK lung cancer
GSK’s neladalkib, branded Nelkarmi, won FDA accelerated approval on 17 November 2026 after ALKOVE-1 produced a 31% response rate in 253 previously treated patients.
TAG V-1848 · 640 words on the filing

Summary of findings
- The FDA granted accelerated approval to neladalkib, branded Nelkarmi, on 17 November 2026.
- ALKOVE-1 reported a 31% objective response rate among 253 patients previously treated with ALK inhibitors.
- Response was approximately 26% after prior lorlatinib; intracranial response was 32% in 92 patients with measurable CNS lesions.
- Approximately 17% needed dose reductions, while around 5% discontinued treatment because of adverse reactions.
- GSK acquired Nuvalent for $10.6 billion in 2026; zidesamtinib received FDA approval on 22 July 2026.
By Daniel Okafor
On 17 November 2026, the US Food and Drug Administration (FDA) granted accelerated approval to GSK’s neladalkib, branded Nelkarmi, for advanced ALK-positive non-small cell lung cancer (NSCLC) that progressed after prior ALK tyrosine kinase inhibitor treatment. In Phase I/II ALKOVE-1, the drug delivered a 31% objective response rate among 253 patients who had received ALK inhibitors.
Who can receive neladalkib?
Neladalkib is an ALK inhibitor. In ALK-positive NSCLC, genetic changes involving the ALK gene can let tumour cells reproduce without normal control; treatment aims to block activity of the associated protein.
Approval is narrower than the lung-cancer category. Nelkarmi is not indicated for every lung cancer, and use depends on the tumour’s molecular characteristics, previous treatment and the patient’s clinical condition.
The British drugmaker GSK developed the asset. Its commercial logic addresses resistance: tumours may become less responsive after ALK-targeted therapy, progression follows, and later-line choices can contract.
Takeaway: This is a selected, post-progression option, not a broad NSCLC indication.
What did ALKOVE-1 show?
The approval drew on the international Phase I/II ALKOVE-1 study, which assessed efficacy and safety in advanced ALK-positive lung cancer, particularly after targeted therapy. Published results showed an objective response rate (ORR) in 31% of 253 patients who had previously received ALK inhibitors.
Objective response means tumour shrinkage under established assessment criteria. It does not imply a complete cure or a guaranteed increase in life expectancy. Response is not survival.
Among patients previously treated with lorlatinib, the response rate was approximately 26%. The trial also examined response within the central nervous system (CNS): among 92 patients with measurable CNS lesions, the intracranial response rate was 32%.
The reported endpoint was tumour response. Read the percentages for what they are, not as a cure claim or a guaranteed extension of life.
Takeaway: The response signal is specific and measurable; it is not a cure or survival claim.
What safety findings matter for use?
Trial participants reported several common adverse reactions in ALKOVE-1:
- Elevated liver enzyme levels
- Constipation
- Changes in taste perception
- Oedema
- Cough
- Nausea
Approximately 17% of participants required a dose reduction because of adverse reactions, while around 5% discontinued treatment.
Those rates describe the study group and need not match an individual patient’s risk. An oncologist should choose treatment after considering prior therapy, the tumour’s molecular profile, possible interactions with other medicines and contraindications.
Takeaway: Most participants did not need a dose cut or stop, but individual risk still requires clinical review.
What does accelerated approval change?
FDA’s Accelerated Approval pathway can bring promising medicines for serious diseases to patients sooner when preliminary trial results indicate potential clinical benefit. For neladalkib, that means accelerated access before the FDA had definitively confirmed efficacy across all clinical indicators.
GSK must conduct further studies to demonstrate the drug’s actual clinical benefit. If the expected effect fails to appear, FDA may review or revoke the authorisation. As of 17 November 2026, GSK still needed further studies to confirm long-term clinical benefit.
Takeaway: Approval accelerates access; confirmatory evidence still determines the authorisation’s durability.
What does this mean for GSK’s lung-cancer portfolio?
Neladalkib joined GSK through the company’s $10.6 billion acquisition of US biotechnology company Nuvalent in 2026. The deal brought two assets targeting separate molecular subtypes of non-small cell lung cancer: neladalkib in ALK-positive disease and zidesamtinib in ROS1-positive lung cancer.
The FDA approved zidesamtinib on 22 July 2026. Nelkarmi’s approval broadens the treatment options for ALK-positive patients whose previous targeted therapy proved insufficiently effective.
No information was available on neladalkib’s registration in Ukraine as of 17 November 2026.
Takeaway: The Nuvalent deal now supplies GSK with two recently approved, molecularly targeted lung-cancer medicines.
via FDA industry wire (Google News) (Source)
More from Daniel Okafor
Show full bio
Correspondent covering technology and product news in global pharmaceutical industry at PharmInsider.
5 articles
Linked filings
- C-6506
- C-7994
- C-9698
- P-9899
- K-5457